A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
Identifieur interne : 001310 ( Main/Exploration ); précédent : 001309; suivant : 001311A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
Auteurs : Sarah B. Goldberg [États-Unis] ; Jeffrey G. Supko ; Joel W. Neal ; Alona Muzikansky ; Subba Digumarthy ; Panos Fidias ; Jennifer S. Temel ; Rebecca S. Heist ; Alice T. Shaw ; Patricia O. Mccarthy ; Thomas J. Lynch ; Sreenath Sharma ; Jeffrey E. Settleman ; Lecia V. SequistSource :
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (anatomopathologie), Adénocarcinome (traitement médicamenteux), Antienzymes (pharmacocinétique), Antienzymes (usage thérapeutique), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Dose maximale tolérée, Femelle, Humains, Hydroxychloroquine (pharmacocinétique), Hydroxychloroquine (usage thérapeutique), Immunosuppresseurs (pharmacocinétique), Immunosuppresseurs (usage thérapeutique), Mutation (génétique), Mâle, Pronostic, Protocoles de polychimiothérapie antinéoplasique, Récepteurs ErbB (antagonistes et inhibiteurs), Récepteurs ErbB (génétique), Répartition dans les tissus, Sirolimus (analogues et dérivés), Sirolimus (pharmacocinétique), Sirolimus (usage thérapeutique), Stade de la tumeur, Sujet âgé, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (traitement médicamenteux), Études de suivi, Évérolimus.
- MESH :
- analogues et dérivés : Sirolimus.
- anatomopathologie : Adénocarcinome, Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- antagonistes et inhibiteurs : Récepteurs ErbB.
- génétique : Mutation, Récepteurs ErbB.
- pharmacocinétique : Antienzymes, Hydroxychloroquine, Immunosuppresseurs, Sirolimus.
- traitement médicamenteux : Adénocarcinome, Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- usage thérapeutique : Antienzymes, Hydroxychloroquine, Immunosuppresseurs, Sirolimus.
- Adulte, Adulte d'âge moyen, Dose maximale tolérée, Femelle, Humains, Mâle, Pronostic, Protocoles de polychimiothérapie antinéoplasique, Répartition dans les tissus, Stade de la tumeur, Sujet âgé, Études de suivi, Évérolimus.
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (pathology), Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (pathology), Enzyme Inhibitors (pharmacokinetics), Enzyme Inhibitors (therapeutic use), ErbB Receptors (antagonists & inhibitors), ErbB Receptors (genetics), Everolimus, Female, Follow-Up Studies, Humans, Hydroxychloroquine (pharmacokinetics), Hydroxychloroquine (therapeutic use), Immunosuppressive Agents (pharmacokinetics), Immunosuppressive Agents (therapeutic use), Lung Neoplasms (drug therapy), Lung Neoplasms (pathology), Male, Maximum Tolerated Dose, Middle Aged, Mutation (genetics), Neoplasm Staging, Prognosis, Sirolimus (analogs & derivatives), Sirolimus (pharmacokinetics), Sirolimus (therapeutic use), Tissue Distribution.
- MESH :
- chemical , analogs & derivatives : Sirolimus.
- chemical , antagonists & inhibitors : ErbB Receptors.
- chemical , genetics : ErbB Receptors.
- chemical , pharmacokinetics : Enzyme Inhibitors, Hydroxychloroquine, Immunosuppressive Agents, Sirolimus.
- drug therapy : Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- genetics : Mutation.
- pathology : Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- chemical , therapeutic use : Enzyme Inhibitors, Hydroxychloroquine, Immunosuppressive Agents, Sirolimus.
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Everolimus, Female, Follow-Up Studies, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Prognosis, Tissue Distribution.
Abstract
This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer.
DOI: 10.1097/JTO.0b013e318262de4a
PubMed: 22878749
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000355
- to stream PubMed, to step Curation: 000355
- to stream PubMed, to step Checkpoint: 000361
- to stream Ncbi, to step Merge: 000180
- to stream Ncbi, to step Curation: 000180
- to stream Ncbi, to step Checkpoint: 000180
- to stream Main, to step Merge: 001311
- to stream Main, to step Curation: 001310
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.</title>
<author><name sortKey="Goldberg, Sarah B" sort="Goldberg, Sarah B" uniqKey="Goldberg S" first="Sarah B" last="Goldberg">Sarah B. Goldberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Supko, Jeffrey G" sort="Supko, Jeffrey G" uniqKey="Supko J" first="Jeffrey G" last="Supko">Jeffrey G. Supko</name>
</author>
<author><name sortKey="Neal, Joel W" sort="Neal, Joel W" uniqKey="Neal J" first="Joel W" last="Neal">Joel W. Neal</name>
</author>
<author><name sortKey="Muzikansky, Alona" sort="Muzikansky, Alona" uniqKey="Muzikansky A" first="Alona" last="Muzikansky">Alona Muzikansky</name>
</author>
<author><name sortKey="Digumarthy, Subba" sort="Digumarthy, Subba" uniqKey="Digumarthy S" first="Subba" last="Digumarthy">Subba Digumarthy</name>
</author>
<author><name sortKey="Fidias, Panos" sort="Fidias, Panos" uniqKey="Fidias P" first="Panos" last="Fidias">Panos Fidias</name>
</author>
<author><name sortKey="Temel, Jennifer S" sort="Temel, Jennifer S" uniqKey="Temel J" first="Jennifer S" last="Temel">Jennifer S. Temel</name>
</author>
<author><name sortKey="Heist, Rebecca S" sort="Heist, Rebecca S" uniqKey="Heist R" first="Rebecca S" last="Heist">Rebecca S. Heist</name>
</author>
<author><name sortKey="Shaw, Alice T" sort="Shaw, Alice T" uniqKey="Shaw A" first="Alice T" last="Shaw">Alice T. Shaw</name>
</author>
<author><name sortKey="Mccarthy, Patricia O" sort="Mccarthy, Patricia O" uniqKey="Mccarthy P" first="Patricia O" last="Mccarthy">Patricia O. Mccarthy</name>
</author>
<author><name sortKey="Lynch, Thomas J" sort="Lynch, Thomas J" uniqKey="Lynch T" first="Thomas J" last="Lynch">Thomas J. Lynch</name>
</author>
<author><name sortKey="Sharma, Sreenath" sort="Sharma, Sreenath" uniqKey="Sharma S" first="Sreenath" last="Sharma">Sreenath Sharma</name>
</author>
<author><name sortKey="Settleman, Jeffrey E" sort="Settleman, Jeffrey E" uniqKey="Settleman J" first="Jeffrey E" last="Settleman">Jeffrey E. Settleman</name>
</author>
<author><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22878749</idno>
<idno type="pmid">22878749</idno>
<idno type="doi">10.1097/JTO.0b013e318262de4a</idno>
<idno type="wicri:Area/PubMed/Corpus">000355</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000355</idno>
<idno type="wicri:Area/PubMed/Curation">000355</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000355</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000361</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000361</idno>
<idno type="wicri:Area/Ncbi/Merge">000180</idno>
<idno type="wicri:Area/Ncbi/Curation">000180</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000180</idno>
<idno type="wicri:Area/Main/Merge">001311</idno>
<idno type="wicri:Area/Main/Curation">001310</idno>
<idno type="wicri:Area/Main/Exploration">001310</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.</title>
<author><name sortKey="Goldberg, Sarah B" sort="Goldberg, Sarah B" uniqKey="Goldberg S" first="Sarah B" last="Goldberg">Sarah B. Goldberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Supko, Jeffrey G" sort="Supko, Jeffrey G" uniqKey="Supko J" first="Jeffrey G" last="Supko">Jeffrey G. Supko</name>
</author>
<author><name sortKey="Neal, Joel W" sort="Neal, Joel W" uniqKey="Neal J" first="Joel W" last="Neal">Joel W. Neal</name>
</author>
<author><name sortKey="Muzikansky, Alona" sort="Muzikansky, Alona" uniqKey="Muzikansky A" first="Alona" last="Muzikansky">Alona Muzikansky</name>
</author>
<author><name sortKey="Digumarthy, Subba" sort="Digumarthy, Subba" uniqKey="Digumarthy S" first="Subba" last="Digumarthy">Subba Digumarthy</name>
</author>
<author><name sortKey="Fidias, Panos" sort="Fidias, Panos" uniqKey="Fidias P" first="Panos" last="Fidias">Panos Fidias</name>
</author>
<author><name sortKey="Temel, Jennifer S" sort="Temel, Jennifer S" uniqKey="Temel J" first="Jennifer S" last="Temel">Jennifer S. Temel</name>
</author>
<author><name sortKey="Heist, Rebecca S" sort="Heist, Rebecca S" uniqKey="Heist R" first="Rebecca S" last="Heist">Rebecca S. Heist</name>
</author>
<author><name sortKey="Shaw, Alice T" sort="Shaw, Alice T" uniqKey="Shaw A" first="Alice T" last="Shaw">Alice T. Shaw</name>
</author>
<author><name sortKey="Mccarthy, Patricia O" sort="Mccarthy, Patricia O" uniqKey="Mccarthy P" first="Patricia O" last="Mccarthy">Patricia O. Mccarthy</name>
</author>
<author><name sortKey="Lynch, Thomas J" sort="Lynch, Thomas J" uniqKey="Lynch T" first="Thomas J" last="Lynch">Thomas J. Lynch</name>
</author>
<author><name sortKey="Sharma, Sreenath" sort="Sharma, Sreenath" uniqKey="Sharma S" first="Sreenath" last="Sharma">Sreenath Sharma</name>
</author>
<author><name sortKey="Settleman, Jeffrey E" sort="Settleman, Jeffrey E" uniqKey="Settleman J" first="Jeffrey E" last="Settleman">Jeffrey E. Settleman</name>
</author>
<author><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name>
</author>
</analytic>
<series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title>
<idno type="eISSN">1556-1380</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term>
<term>Adenocarcinoma (pathology)</term>
<term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term>
<term>Carcinoma, Non-Small-Cell Lung (pathology)</term>
<term>Enzyme Inhibitors (pharmacokinetics)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>ErbB Receptors (antagonists & inhibitors)</term>
<term>ErbB Receptors (genetics)</term>
<term>Everolimus</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Hydroxychloroquine (pharmacokinetics)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immunosuppressive Agents (pharmacokinetics)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Male</term>
<term>Maximum Tolerated Dose</term>
<term>Middle Aged</term>
<term>Mutation (genetics)</term>
<term>Neoplasm Staging</term>
<term>Prognosis</term>
<term>Sirolimus (analogs & derivatives)</term>
<term>Sirolimus (pharmacokinetics)</term>
<term>Sirolimus (therapeutic use)</term>
<term>Tissue Distribution</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Adénocarcinome (anatomopathologie)</term>
<term>Adénocarcinome (traitement médicamenteux)</term>
<term>Antienzymes (pharmacocinétique)</term>
<term>Antienzymes (usage thérapeutique)</term>
<term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term>
<term>Dose maximale tolérée</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hydroxychloroquine (pharmacocinétique)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Immunosuppresseurs (pharmacocinétique)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Mutation (génétique)</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Récepteurs ErbB (antagonistes et inhibiteurs)</term>
<term>Récepteurs ErbB (génétique)</term>
<term>Répartition dans les tissus</term>
<term>Sirolimus (analogues et dérivés)</term>
<term>Sirolimus (pharmacocinétique)</term>
<term>Sirolimus (usage thérapeutique)</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
<term>Études de suivi</term>
<term>Évérolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>ErbB Receptors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>ErbB Receptors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Enzyme Inhibitors</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs ErbB</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Mutation</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Mutation</term>
<term>Récepteurs ErbB</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antienzymes</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Enzyme Inhibitors</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Everolimus</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Maximum Tolerated Dose</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Prognosis</term>
<term>Tissue Distribution</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Dose maximale tolérée</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Répartition dans les tissus</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Études de suivi</term>
<term>Évérolimus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><noCountry><name sortKey="Digumarthy, Subba" sort="Digumarthy, Subba" uniqKey="Digumarthy S" first="Subba" last="Digumarthy">Subba Digumarthy</name>
<name sortKey="Fidias, Panos" sort="Fidias, Panos" uniqKey="Fidias P" first="Panos" last="Fidias">Panos Fidias</name>
<name sortKey="Heist, Rebecca S" sort="Heist, Rebecca S" uniqKey="Heist R" first="Rebecca S" last="Heist">Rebecca S. Heist</name>
<name sortKey="Lynch, Thomas J" sort="Lynch, Thomas J" uniqKey="Lynch T" first="Thomas J" last="Lynch">Thomas J. Lynch</name>
<name sortKey="Mccarthy, Patricia O" sort="Mccarthy, Patricia O" uniqKey="Mccarthy P" first="Patricia O" last="Mccarthy">Patricia O. Mccarthy</name>
<name sortKey="Muzikansky, Alona" sort="Muzikansky, Alona" uniqKey="Muzikansky A" first="Alona" last="Muzikansky">Alona Muzikansky</name>
<name sortKey="Neal, Joel W" sort="Neal, Joel W" uniqKey="Neal J" first="Joel W" last="Neal">Joel W. Neal</name>
<name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name>
<name sortKey="Settleman, Jeffrey E" sort="Settleman, Jeffrey E" uniqKey="Settleman J" first="Jeffrey E" last="Settleman">Jeffrey E. Settleman</name>
<name sortKey="Sharma, Sreenath" sort="Sharma, Sreenath" uniqKey="Sharma S" first="Sreenath" last="Sharma">Sreenath Sharma</name>
<name sortKey="Shaw, Alice T" sort="Shaw, Alice T" uniqKey="Shaw A" first="Alice T" last="Shaw">Alice T. Shaw</name>
<name sortKey="Supko, Jeffrey G" sort="Supko, Jeffrey G" uniqKey="Supko J" first="Jeffrey G" last="Supko">Jeffrey G. Supko</name>
<name sortKey="Temel, Jennifer S" sort="Temel, Jennifer S" uniqKey="Temel J" first="Jennifer S" last="Temel">Jennifer S. Temel</name>
</noCountry>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Goldberg, Sarah B" sort="Goldberg, Sarah B" uniqKey="Goldberg S" first="Sarah B" last="Goldberg">Sarah B. Goldberg</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001310 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001310 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:22878749 |texte= A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22878749" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |